Abstract:For many decades it has been known that tumor DNA is shed into the blood. As a consequence of technological limitations, researchers were unable to comprehensively characterize circulating DNA. The advent of ultrasensitive and highly specific molecular assays has provided a comprehensive profile of the molecular characteristics and dynamics of circulating DNA in healthy subjects and cancer patients. With these new tools in hand, significant interest has been provoked for an innovative type of tumor biopsy termed a "liquid biopsy". Liquid biopsies are obtained by minimal invasive blood draws from cancer patients. Circulating cancer cells, exosomes and a variety of molecules contained within the liquid biopsy including cell-free circulating tumor DNA (ctDNA) can serve as promising tools to track cancer evolution. Attractive features of ctDNA are that ctDNA isolation is straightforward, ctDNA levels increase or decrease in response to the degree of tumor burden and ctDNA contains DNA mutations found in both primary and metastatic lesions. Consequently, the analysis of circulating DNA for cancer-specific mutations might prove to be a valuable tool for cancer detection. Moreover, the capacity to screen for ctDNA in serial liquid biopsies offers the possibility to monitor tumor progression and responses to therapy and to influence treatment decisions that ultimately may improve patient survival. Here we focus on mutation detection in ctDNA and provide an overview of the characteristics of ctDNA, detection methods for ctDNA and the feasibility of ctDNA to monitor tumor dynamics. Current challenges associate with ctDNA will also be discussed.

Progress in the Application of Ctdna on the Cancer Diagnosis and Prognosis

Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer

"Liquid biopsy"-ctDNA detection with great potential and challenges.

Circulating tumor DNA in liquid biopsy: Current diagnostic limitation

Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy

Progresses on Detection Technology of Circulating Tumor DNA

[Advances in Liquid Biopsy and Its Clinical Application in the Diagnosis and Treatment of Non-small Cell Lung Cancer].

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy.

Blood-based Tumor Markers in Lung Cancer

A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques

The functional and clinical roles of liquid biopsy in patient-derived models

Advances in Detection and Clinical Application of Circulating Tumor DNA

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

The Detection of Circulating Tumor DNA: from Digitalization to Sequencing

Liquid biopsy: unlocking the potentials of cell-free DNA

Cell-free Circulating Tumor DNA in Cancer

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer